PortugalPortugal

Iberian support for new flu vaccine

12.07.2009

Madrid –The Spanish Ministry of Health is investing in future biotech treatments. In July, it signed a EUR60m contract over a recombinantly manufactured flu vaccine developed by Rockville-based Novavax.
In Phase II trials, the company is currently testing a vaccine based on virus-like particles without viral RNA. Novavax hopes to develop pandemic and seasonal flu vaccines, and plans to seek regulatory approval by 2012 in Europe.
The company will develop the vaccines with Spanish drugmaker ROVI Pharmaceuticals. Under separate agreements that are being negotiated by both companies, ROVI will receive exclusive licenses to Novavax’s portable VLP vaccine technology to commercialise flu vaccines in Spain and Portugal, and non-exclusive licenses in Europe, Latin America and Africa. Furthermore, under a stock purchase agreement, ROVI has committed to make a US$3m equity investment in Novavax at $2.74 per share,
To acccomplish the deal, ROVI and the Spanish authorities will establish a joint non-profit foundation to be initially funded with a a25m line of credit from the Spanish government. The funds will support Phase III clinical development and other studies necessary to achieve marketing authorisation of the VLP influenza vaccines.
Additional clinical development funds will be contributed by ROVI if required. In addition, the State of Andalucía will support the drugmaker in building a new VLP vaccine plant in Granada, and bring it on-line in 2012 at a cost of EUR20m. The plant is expected to have enough manufacturing capacity to service Spain and other parts of Europe, Latin America, and Africa.

PortugalPortugal

02.12.2011

Lisbon – Genetically modified organisms (GMOs) are gaining ground in southwestern Europe. According to the European Association for Bioindustries (EuropaBio), Portuguese farmers planted nearly 60% more genetically modified maize...

PortugalPortugal

07.10.2011

Lisbon – In the southwest of Europe, GMOs are gaining ground. According to the European Association for BioIndustries EuropaBio, Portuguese farmers have grown nearly 60% more genetically modified (GM) maize this year compared to...

PortugalPortugal

11.08.2011

Lisbon – According to a report published by business intelligence provider Espicom, the future for biopharma on the westernmost tip of Europe looks anything but sunny. Its analysts predict that by 2016, the pharmaceuticals market...

PortugalPortugal

08.03.2010

Lisbon – Portugal’s “Fundação para a Ciência e Tecnologia” (FCT) is to channel funding into collaborations between Portuguese and Indian life science companies and research within the networking pilot programme “New Indigo”...

PortugalPortugal

14.09.2009

Coimbra/San Francisco/Munster – Portuguese and US researchers have discovered a new factor that determines whether an embryonic stem cell (ESC) will remain pluripotent or not. After the team under Miguel and Joao Ramalho-Santos...

09.05.2009

Lisbon/New York - A Portuguese-US research team has discovered a new molecular mechanism that enables gamma herpes viruses to chronically infect patients. Gamma herpes viruses infect white blood cells (B- or T-lymphocytes)...

PortugalPortugal

21.02.2009

Lisbon – Portugal’s Bial SA has granted American company Sepracor the exclusive rights to develop and commercialise eslicarbazepine in the United States and Canada. Bial will receive US$57m up front.

PortugalPortugal

03.11.2008

Poco Barreto – In mid-August, 60 anti-GMO activists destroyed a field planted with insect-resistant Mon810 maize in Portugal. Near the small Algarve town of Poco Barreto, activists from the “Movimento Verde Eufemia” trampled...

Displaying results 1 to 10 out of 37

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-portugal/article/iberian-support-for-new-flu-vaccine.html

Events

All Events

Stock list

All quotes

TOP

  • EVOTEC3.94 EUR8.54%
  • VITA 343.90 EUR4.00%
  • SANTHERA86.50 CHF3.59%

FLOP

  • WILEX2.30 EUR-2.54%
  • 4SC1.22 EUR-2.40%
  • ADDEX3.99 CHF-1.97%

TOP

  • SANTHERA86.50 CHF32.1%
  • BB BIOTECH144.50 EUR9.3%
  • BASILEA103.90 CHF4.4%

FLOP

  • WILEX2.30 EUR-17.9%
  • MOLOGEN7.84 EUR-17.5%
  • 4SC1.22 EUR-14.1%

TOP

  • SANTHERA86.50 CHF3831.8%
  • CO.DON2.57 EUR221.2%
  • PAION2.46 EUR182.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.55 EUR-66.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 27.08.2014


Current issue

All issues

Product of the week

Products